Novartis Gene Therapies
E1555622
UNEXPLORED
Novartis Gene Therapies is a biotechnology company within Novartis focused on developing and commercializing gene therapy treatments for rare and life-threatening genetic diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Novartis Gene Therapies canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22797003 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Novartis Gene Therapies Context triple: [AveXis, changedNameTo, Novartis Gene Therapies]
-
A.
CRISPR Therapeutics
CRISPR Therapeutics is a biotechnology company focused on developing gene-editing therapies using CRISPR/Cas9 technology to treat serious diseases.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
D.
BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
-
E.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Novartis Gene Therapies Target entity description: Novartis Gene Therapies is a biotechnology company within Novartis focused on developing and commercializing gene therapy treatments for rare and life-threatening genetic diseases.
-
A.
CRISPR Therapeutics
CRISPR Therapeutics is a biotechnology company focused on developing gene-editing therapies using CRISPR/Cas9 technology to treat serious diseases.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
D.
BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
-
E.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.